Cholesterol drug to reduce inflammation after heart bypass surgery
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a medicine that lowers cholesterol can also reduce inflammation and protect organs during and after heart bypass surgery. If you are having bypass surgery soon, this study may help improve your recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a heart condition that reduces blood flow to the heart muscle (like a heart attack or severe chest pain).
- You are scheduled to have heart bypass surgery (CABG) within the next month.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study and for 3 months after if you could become pregnant.
- You have not used a PCSK9 inhibitor (a cholesterol-lowering injectable medicine) in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
This trial tests whether a single dose of a cholesterol-lowering drug called a PCSK9 inhibitor can improve heart outcomes after a stent procedure. If you recently had a stent and the imaging showed significant plaque, this may help reduce future risks.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
Hear when a new Coronary Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.